Bullish & Foolish
Full NRXS fundamentals All 466 on the Survival Watch

NRXSNEURAXIS, INC.

Is Neuraxis struggling financially?

Yes, by its own account. Neuraxis told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$77.2M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 13months

    If the burn speeds up

    Empty by Jul 2027

  • 18months

    If it eases off

    Empty by Dec 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$8.3M

÷

Cash burned over the last 12 months

$6.5M

What Neuraxis told the SEC

…nor management’s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern. As the Company continue to incur losses, the transition to profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may never achieve…

NEURAXIS, INC., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 46.0% share-count increase The company issued stock. Each share now owns 31.5% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 40% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt